MedImmune Inc., American Home Products sales and marketing update

MEDI began U.S. sales of RespiGam immune globulin iv for respiratory syncytial virus (RSV). RespiGam was approved on Jan. 18th for the prevention of RSV in children under 24 months of age with bronchopulmonary dysplasia or who were prematurely born. The immune globulin has an average price of $4,543 per RSV season, depending on the child's weight.

The company expects modest sales for the rest of this RSV season, which runs from early November through April, and plans a full launch for fall 1996. ...